AU2019358324B2 - GLP-1 receptor antagonists - Google Patents

GLP-1 receptor antagonists Download PDF

Info

Publication number
AU2019358324B2
AU2019358324B2 AU2019358324A AU2019358324A AU2019358324B2 AU 2019358324 B2 AU2019358324 B2 AU 2019358324B2 AU 2019358324 A AU2019358324 A AU 2019358324A AU 2019358324 A AU2019358324 A AU 2019358324A AU 2019358324 B2 AU2019358324 B2 AU 2019358324B2
Authority
AU
Australia
Prior art keywords
vehicle
compound according
syndrome
lysr
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019358324A
Other languages
English (en)
Other versions
AU2019358324A1 (en
Inventor
Giles Albert Brown
Miles Stuart Congreve
Conor SCULLY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nxera Pharma UK Ltd
Original Assignee
Nxera Pharma UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nxera Pharma UK Ltd filed Critical Nxera Pharma UK Ltd
Publication of AU2019358324A1 publication Critical patent/AU2019358324A1/en
Assigned to NXERA PHARMA UK LIMITED reassignment NXERA PHARMA UK LIMITED Amend patent request/document other than specification (104) Assignors: HEPTARES THERAPEUTICS LIMITED
Application granted granted Critical
Publication of AU2019358324B2 publication Critical patent/AU2019358324B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2019358324A 2018-10-12 2019-10-14 GLP-1 receptor antagonists Active AU2019358324B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1816639.7A GB201816639D0 (en) 2018-10-12 2018-10-12 GLP-1 Receptor Antagonist
GB1816639.7 2018-10-12
PCT/GB2019/052915 WO2020074927A2 (en) 2018-10-12 2019-10-14 Glp-1 receptor antagonists

Publications (2)

Publication Number Publication Date
AU2019358324A1 AU2019358324A1 (en) 2021-04-22
AU2019358324B2 true AU2019358324B2 (en) 2025-05-22

Family

ID=64397527

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019358324A Active AU2019358324B2 (en) 2018-10-12 2019-10-14 GLP-1 receptor antagonists

Country Status (8)

Country Link
US (2) US12441777B2 (https=)
EP (1) EP3863661A2 (https=)
JP (1) JP7492507B2 (https=)
CN (1) CN113166206A (https=)
AU (1) AU2019358324B2 (https=)
CA (1) CA3115448A1 (https=)
GB (1) GB201816639D0 (https=)
WO (1) WO2020074927A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202011604D0 (en) * 2020-07-27 2020-09-09 Heptares Therapeutics Ltd GLP-1 receptor antagonists
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120087863A1 (en) * 2010-10-08 2012-04-12 Arkray, Inc. Peptide Derivative and Use of the Same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399489B2 (en) 1999-01-14 2008-07-15 Amylin Pharmaceuticals, Inc. Exendin analog formulations
CN100540565C (zh) 2005-01-14 2009-09-16 无锡宏创医药科技有限公司 修饰的Exendins及其应用
WO2007139941A2 (en) 2006-05-26 2007-12-06 Amylin Pharmaceuticals, Inc. Composition and methods for treatment of congestive heart failure
WO2010032509A1 (ja) * 2008-09-20 2010-03-25 国立大学法人京都大学 膵島イメージング用分子プローブ前駆体及びその使用
WO2010120476A2 (en) 2009-04-01 2010-10-21 Amylin Pharmaceuticals, Inc. N-terminus conformationally constrained glp-1 receptor agonist compounds
CN101870728A (zh) 2009-04-23 2010-10-27 派格生物医药(苏州)有限公司 新型Exendin变体及其缀合物
WO2011027584A1 (ja) * 2009-09-04 2011-03-10 国立大学法人京都大学 膵島イメージング用分子プローブ及びその使用
CN102532301B (zh) * 2010-12-31 2014-09-03 上海医药工业研究院 一类新型的Exendin-4类似物及其制备方法
GB201315335D0 (en) * 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
LT3297653T (lt) * 2015-05-22 2022-01-10 The Board Of Trustees Of The Leland Stanford Junior University Postbariatrinės hipoglikemijos gydymas glp-1 antagonistais

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120087863A1 (en) * 2010-10-08 2012-04-12 Arkray, Inc. Peptide Derivative and Use of the Same

Also Published As

Publication number Publication date
AU2019358324A1 (en) 2021-04-22
CA3115448A1 (en) 2020-04-16
JP7492507B2 (ja) 2024-05-29
US12441777B2 (en) 2025-10-14
CN113166206A (zh) 2021-07-23
US20250368709A1 (en) 2025-12-04
US20210355186A1 (en) 2021-11-18
GB201816639D0 (en) 2018-11-28
WO2020074927A2 (en) 2020-04-16
JP2022504798A (ja) 2022-01-13
WO2020074927A3 (en) 2020-12-17
EP3863661A2 (en) 2021-08-18

Similar Documents

Publication Publication Date Title
US20250368709A1 (en) Glp-1 receptor antagonists
CN107207576B (zh) Gip和glp-1共激动剂化合物
AU2007319066B2 (en) Selective glucagon-like-peptide-2 (GLP-2) analogues
WO2014198880A1 (en) 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity
TW201427992A (zh) 作為雙重ｇｌｐ１／升糖素激動劑之艾塞那肽－４衍生物
US20230279053A1 (en) Glp-1 receptor antagonists
EP4121093A1 (en) Glp receptor agonists
US11987648B2 (en) Cyclohexapeptides as selective somatostatin SST5 receptor agonists
CN115960258B (zh) 一类GLP-1/glucagon/Y2受体三重激动剂及其应用
CA3175430A1 (en) Oral glp receptor agonists
EP4225772B1 (en) Cyclic apelin receptor agonists
RU2836443C1 (ru) Пероральные агонисты рецепторов glp
WO2026073030A1 (en) Combination therapy of peptide tyrosine-tyrosine (pyy) analogues and glp-1r agonists
US20230391730A1 (en) Inhibitors of the bromodomain phd finger transcription factor (bptf) as anti-cancer agents
CN109761990B (zh) 一种嘧啶并嘧啶类衍生物及其制备方法和在医药上的应用
WO2023144736A1 (en) Compositions for preventing or treating pulmonary arterial hypertension

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: NXERA PHARMA UK LIMITED

Free format text: FORMER NAME(S): HEPTARES THERAPEUTICS LIMITED

FGA Letters patent sealed or granted (standard patent)